| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |